KAI (kī) Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. KAI’s lead product candidate, KAI-9803, is partnered with Bristol-Myers Squibb and has demonstrated efficacy in reducing damage to heart muscle and improving cardiac function in patients with myocardial infarction (MI) who undergo balloon angioplasty. KAI’s second clinical program, KAI-1678, is a promising first-in-class drug candidate that may address both the inflammatory and neuropathic pain markets. KAI’s third program, KAI-4169 , is for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients.
KAI’s expertise is in the selective modulation of intracellular protein:protein interactions via delivery of peptide drugs into the cell. The Company has applied its core technology to discover highly potent and selective inhibitors and activators for validated members of the protein kinase C (PKC) family of isozymes. This approach has demonstrated therapeutic potential clinically and in many preclinical disease models.
|
|
KAI currently is enrolling patients in a Phase 2b study of KAI-9803. The Phase 2b trial (PROTECTION AMI) is designed to assess the effect of KAI-9803 on reducing myocardial injury in patients with ST segment elevation myocardial infarction (STEMI) who are undergoing percutaneous coronary intervention (PCI). [